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OBJECTIVES: To evaluate the effectiveness and safety of pleurodesis carried out entirely on an outpatient basis in
patients with recurrent malignant pleural effusions and Karnofsky Performance Status scores #70.
METHODS: This study was a prospective trial comprising patients with symptomatic recurrent malignant pleural
effusion and Karnofsky Performance Status scores #70 but .30. All selected patients underwent pleural catheter
placement (14 Fr) in an outpatient facility. When chest radiography revealed post-drainage lung expansion of
.90%, pleurodesis (3 g of talc) was performed. Catheters were maintained until the daily output was ,100 mL/day.
The patients were evaluated in the first month and every three months thereafter for fluid recurrence, the need for
additional procedures, and complications.
RESULTS: During the study period (January 2005 to July 2007), 64 patients (24 men, 40 women), with an average age
of 61.4 years, underwent elective chest tube drainage. Primary sites of the underlying malignancy were breast (27),
lung (22), and others (15). Sixty-six pleural catheters were placed (bilaterally in 2 patients), and 52 talc pleurodesis
procedures were performed. Fourteen patients had a trapped lung and were excluded from the trial. No
complications were observed during catheter placement or pleurodesis. Post-pleurodesis complications included
catheter obstruction (4 patients) and empyema (1). The average drainage time was 9.9 days. The recurrence rate
observed in patients that were alive 30 days after pleurodesis was 13.9% (5/36 patients). Six patients required
additional procedures after the pleurodesis. The average survival time was 101 days.
CONCLUSION: In this study, talc pleurodesis was safely performed in an outpatient setting with good efficacy and a
reasonable complication rate, thereby avoiding hospital admission.
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INTRODUCTION
Malignant pleural effusion (MPE) is a frequent and
disturbing complication of metastatic disease, and pleurod-
esis is the procedure that is traditionally used to control
MPE.1 Talc is an effective sclerosing agent and has wide
international acceptance;1-3 nonetheless, intrapleural admin-
istration of talc, which can be done via videothoracoscopy
or chest tube, requires hospital admission.3-7 This fact,
which is particularly undesirable for patients with advanced
disease receiving palliative treatment, has prompted the
search for new, less invasive procedures that could be
performed on an outpatient basis. This discussion is even
more relevant for patients with low performance status
(Karnofsky Performance Status [KPS] ,70), for whom life
expectancy is particularly limited,8-10 reason why they are
usually relegated to repeated thoracenteses, a procedure
with a high level of recurrence.11 Particularly, for this
subgroup of patients, a minimally invasive procedure for
the control of MPE that dispenses with the need for hospital
admission is of paramount importance. The feasibility of
performing pleurodesis on an outpatient basis, through the
use of pleural catheters, was suggested in a series of just 10
cases12 and, although it appears to be a good alternative, no
further studies have addressed this issue. Therefore, the
objective of this study was to evaluate the effectiveness and
safety of pleurodesis carried out entirely on an outpatient
basis, through talc slurry by pleural catheters in patients
with recurrent MPE and KPS #70.
Copyright  2011 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
CLINICS 2011;66(2):211-216 DOI:10.1590/S1807-59322011000200005
211
MATERIALS AND METHODS
From January 2005 to July 2007, a prospective trial
protocol was conducted in our outpatient Pleural Diseases
Unit. The study included patients with the following
characteristics: 1) biopsy or cytology proven MPE which
was symptomatic and recurrent (according to chest radio-
graphs); and 2) performance status #70 (according to the
KPS). Patients with the following characteristics were
excluded: 1) performance status #30 (according to the
KPS); 2) Incomplete lung expansion after chest tube
drainage (trapped lung) on chest radiograph; 3) social or
cognitive conditions that would prevent home care with the
drain; 4) hemorrhagic diatheses (platelets ,50.000 and INR
. 1.5); 5) active skin infection; 6) neoplastic skin infiltration
at the drainage site; 7) Previous pleurodesis or chest tube
drainage; 8) declining to sign the informed consent.
All patients had their skin examined immediately before
the procedure. All of them also had recent laboratory tests
(maximum 7 days) prior to catheter insertion. Active skin
infection (mainly due to breast cancer) at the site of catheter
insertion was diagnosed through physical examination.
White blood cells count . 12.000 and fever were findings
that supported such a diagnosis. This study protocol was
revised and approved by our Institutional Ethics
Committee.
Procedure
Each included patient signed the informed consent
approved by our institutional ethics committee. All proce-
dures were carried out in the minor procedures room of
our outpatient clinic. In all patients, the skin was prepped
with alcoholic clorhexidine and the surgical field isolated
with sterile drapes. After local anesthetic (lidocaine 2%)
administration, pleural drainage was carried out with 14 Fr
pigtail catheters (C-UPTP-1400-WAYNE, Cook Medical,
Bloomington, IN) using the trocar technique (Figure 1A-
C). After that, a Heimlich valve was connected to the the
drain, and its distal end was connected to a collection bag
(Figure 1D).
Proper catheter placement was evaluated immediately
after the procedure according to adequate pleural fluid
evacuation, absence of hemorrhagic events and physical
examination. Evaluation was performed by a trained
investigator that followed a pre-established protocol, look-
ing for potential complications of catheter placement
(respiratory insufficiency, bleeding, pain and cough). If the
catheter was working properly, the patient was discharged
after 1 hour of observation and radiological exams were
considered unnecessary. Before being discharged, the
patients received instruction on how to care for the drain.
The first visit after catheter placement was scheduled to
the fifth day after the procedure. On the first visit, the
patients underwent a chest radiograph; if this showed
pulmonary expansion greater than 90% of the affected
hemithorax, the patient was selected for pleurodesis,
otherwise the patient was discharged and asked to return
in 7 days. In this case, a new chest radiograph was
performed, similar to what was described previously. If
lung expansion was greater than 90%, the patient was
elected for pleurodesis. If complete chest expansion did not
occur (trapped lung), pleurodesis was not performed and
the patient was excluded from the trial. In such patients, the
drain was kept in place until the daily output was,100 mL/
day.
Patients selected for pleurodesis underwent talc slurry
through the pig-tail catheter (3 g of noncalibrated talc
(Magnesita Refratarios SA: Contagem, Brazil) in 60 mL of
saline solution and 5 mL lidocaine 2%). Systemic analgesia
was administered only when necessary. The drain was kept
closed for 1 hour; after this, the drain was opened and the
patient discharged and instructed to return in 1 week.
Complications after pleurodesis were actively searched after
talc instillation and in each visit through physical examina-
tion and a standardized questionnaire. The drain was
removed if the flow was less than 100 mL/day.
Figure 1 - (A) Pigtail catheter and Heimlich valve. (B and C) Catheter insertion using trocar technique, (D) Drain connected to the
collection bag.
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After drain removal, a return visit was scheduled to the
30th post catheter insertion day, for clinical evaluation and a
new chest radiograph. Thereafter, the visits were each 3
months. On all the return visits, new chest radiographies
and the occurrence of complications were evaluated. If the
patients were symptomatic and there was evidence of fluid
accumulation on the chest radiograph, a thoracentesis was
performed. If there was doubt between fluid accumulation
and tumor progression or lung infiltration, a chest CT scan
was performed. Patients who did not show up for the
scheduled consultation were contacted by telephone.
Unscheduled visits were arranged in cases of clinical need
(recurrences, complications, etc.). Patients were followed
until death or until the end of the study in January, 2008.
Data analysis
The variables considered for analysis of clinical effective-
ness were symptomatic improvement and MPE recurrence.
Symptomatic improvement was evaluated between 7 and 15
days post drainage, with a three-point scale filled out by the
patient: complete improvement (absence or minimal symp-
toms), partial improvement (persistent symptoms but with
significant improvement) or no improvement (all the
symptoms persist). Recurrence was a binary variable
(occurred/did not occur) and was considered to have
occurred when, during the clinical follow-up, after removal
of the drain, the patient presented recurrence of the
symptoms (dyspnea and/or chest pain) associated with
radiological evidence of MPE reaccumulation as revealed on
the chest radiograph (assessed by two independent inves-
tigators). If there was any doubt between fluid reaccumula-
tion and tumor progression, a chest tomography was
performed. The recurrence rate was evaluated for the whole
sample, and for the patients who remained alive 30 days
after pleurodesis.
The following variables were also studied: complications
(both after drainage and pleurodesis as well as during all
follow-up), drainage time and need for additional pleural
procedures. The need for new pleural procedures (thor-
acentesis, pleural drainage or videothoracoscopy) after
removal of the drain was a binary variable (yes/no). Such
procedures were indicated when MPE recurrence or pleural
complications as empyema or hemothorax were diagnosed
by our clinical staff.
Descriptive statistical analysis was used to summarize the
characteristics of the studied patients, success rates of the
pleurodesis, complications, and the need for new pleural
procedures. The impact of nominal factors in the post-
operative lung expansion, recurrences and complications
was analyzed with the Chi-Square or exact Fisher tests.
Logistical regression was used to identify factors associated
with mortality within 30 days and with patient survival. All
analyses were carried out with a level of significance of p
,0.05.
RESULTS
From January 2005 to July 2007, 147 patients with MPE
were seen in our Pleural Diseases Unit and 72 fulfilled the
inclusion criteria. The main reason for a patient not be
included in the study was KPS.70. Eight, out of these 72
patients were eventually excluded for the reasons discrimi-
nated in Figure 2. Therefore, 64 patients were elected for
pleural catheter insertion. These patients underwent 66
pleural catheter implantations (2 patients had bilateral
effusion). The demographic characteristics of the studied
patients are listed in Table 1.
No complications were observed during catheter implan-
tation. Fifty-two patients (78.7%) had lung expansion
greater than 90% of the affected hemithorax, while 14
patients (21.2%) had incomplete lung expansion (trapped
Figure 2 - Flow of the patients. * Those numbers depict the number of catheters placed and therefore the number of drained
hemithoraces (two patients had bilateral procedures). Long-term catheters patients – patients who underwent chest tube placement
but were excluded from the trial.
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lung), and therefore were excluded from the trial. There was
no correlation between the degree of lung expansion and
age, sex, primary cancer site or number of previous
thoracenthesis. Pleurodesis was performed on the first
scheduled return visit to the outpatient clinic in 38 cases
(73%) and on the second visit in 14 (27%). The average time
between catheter insertion and pleurodesis was 4.2 (1–15)
days. No complications were observed immediately after
the talc slurry. The average drainage time was 9.9 (4-26)
days.
Late complications were observed after 5 (9.6%) proce-
dures. Obstruction occurred in 4 (7.7%) patients and was the
most frequently observed complication. In 2 patients the
catheters could be unblocked with a flush of saline, and
drainage resumed spontaneously. In the other 2 patients this
procedure failed, and the catheters were removed. Pleural
empyema occurred in 1 (1.9%) patient. Therapy consisted of
antibiotic treatment and videothoracoscopy, with satisfac-
tory result. There were no deaths related to the procedure.
Bleeding, cellulitis, adult respiratory distress syndrome, air
leak and other complications described in the literature did
not occur in this series.
Clinical effectiveness results and additional pleural
procedures are depicted in table 2. In 4 patients, the analysis
of symptomatic improvement could not be carried out due
either to death or inability of the patient to come to the
consultation due to poor clinical status. Recurrence was
observed in 5/52 patients (9.6%) during the whole study
period. For the patients that were alive after 30 days,
recurrence occurred in 5/36 patients (13.9%). Primary site
cancer, time until pleurodesis, previous oncological treat-
ment, and lung expansion did not correlate with the
recurrences. Additional procedures were necessary in 6
patients (11.5%); in 5 due to recurrence of the effusion (1
videothoracoscopy, 1 chest tube drainage, 3 thoracenthesis)
and in 1 due to pleural empyema (videothoracoscopy).
These events were considered as failure of treatment.
After the 30th day consultation, eight patients were lost to
follow-up and seven of them (patients or their families)
could be contacted by telephone, none of these underwent
new pleural procedures according to the telephone inter-
view but late chest radiographs of these patients could not
be obtained. The median follow-up time for all patients was
60 days. The average survival time after catheter introduc-
tion was 101 and days and 11 patients were still alive at the
end of the data collection. A Kaplan-Meier curve estimating
survival of the included patients is depicted in graphic 1. In
this sample, sex (p = 0.58), primary site (p = 0.07), previous
oncological treatment (p= 0.29), pleurodesis (p = 0.97), lung
expansion (p= 0.69) and symptomatic control (p = 0.1) had
no influence on patient survival.
The 14 patients that were submitted to chest tube
drainage and were excluded from the protocol (trapped
lung patients) were followed in the same manner as those in
the trial. Average drainage time was 26.8 (5-94) days.
Complications occurred in 7 patients (50%), especially in
those with drainage lasting over 21 days. Obstruction
occurred in 2 patients (14.3%), empyema in 4 (28.5%) and
pain in 1 (7.1%). Complete symptomatic improvement was
depicted in 9 patients (69.4%), partial improvement in 2
(15.3%) and no improvement in 2 (15.3%). In 1 patient,
symptomatic improvement analysis could not be measured
due either to death or inability of the patient to come to the
consultation. Due to the high rate of complications in this
subset of patients, it is no longer our policy to maintain
drainage over 7 days in patients with partial or no lung
expansion.
DISCUSSION
In the present study we observed that pleurodesis may be
performed in an outpatient setting safely with good efficacy
and reasonable complication rate even in a subgroup of
patients with low performance status. The trial protocol was
easy to implement and required only adaptation of an
already existing wound-care room in our outpatient facility
and training of the nursery team on how to instruct patients
and their caretakers in the care of the pleural catheter at
home. No complications occurred during catheter insertion
or during pleurodesis, and the procedures could be carried
out comfortably in this outpatient clinic environment. As a
minimally invasive procedure, outpatient pleurodesis was
easily accepted by patients and referring physicians.
Moreover, as hospital admission and operation room
scheduling were not necessary, the time from the first
consultation at our clinic to the therapeutic procedure
shortened.
Table 1 - Characteristics of the patients elected for chest
drainage.
Sex (M/F), n 24/40
Age (years) 61.4 (39-87)
Affected side (R/L/B), n 34/28/2
Time from diagnosis until pleurodesis
(months)
2 (1-13)
Previous Thoracenthesis(n)* 3 (1-7)
Primary Site (n)
Breast 27
Lung 22
Undetermined 7
Kidney 3
Others** 5
Oncological Treatment (n)
Thoracic radiotherapy 14
Chemotherapy (ongoing) 20
None 25
Pleural Fluid Characteristics
Oncotic cytology (pos/neg) 34/10
pH 7.2 (6.8-7.7)
Glucose (mg/dL) 88 (11-190)
Protein (g/dL) 4.3 (1.7-6.2)
DHL (U/L) 709 (92-6194)
ADA (U/L) 22.1 (9.7-113.6)
Thoracentesis*: Number of thoracentesis prior to pleurodesis
Others**: Lymphoma, ovarian carcinoma, laryngeal carcinoma.
Results are expressed as median (+range)
Table 2 - Clinical Effectiveness and Additional Pleural
Procedures.
Pleurodesis (n = 52)
Symptomatic
Improvement (n= 48)
Complete 31 (64.5%)
Partial 17 (35.5%)
No 0
Recurrence (30 days)
(n = 36)
5/36 (13.9%)
Additional Pleural
Procedures (n = 6)
Videothoracoscopy 2 (38%)
Chest Tube Drainage 1 (1.9%)
Thoracentesis 3 (65.7%)
Outpatient Pleurodesis
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Our results showed that MPE recurrence occurred in
13.9% of the patients who remained alive 30 days after the
procedure, a result comparable with the recurrence rate of
6–28% observed in other pleurodesis series using either
videothoracoscopy or chest tube.4-8,13,14 Nonetheless, from
an intention-to-treat perspective, 30 (57.6%) procedures out
of 52 could be considered successful (i.e., patients were alive
30 days after the procedure with no recurrence and no need
of additional procedure). Unfortunately this result reflects
general daily practice and this fact was already pointed out
by another article15 in which the authors have analyzed
pleurodesis outcome from an intention-to-treat perspective
and reported a success rate of only 25%, even though they
have considered success when patients were free of pleural
effusion 60 days after the pleurodesis. Such low success
rates reinforce the search for both better predictors and
minimally invasive techniques that dispense with hospital
admission.
Recently another option for MPE management has been
consistently reported, the use of long-term indwelling
catheters.16,17 These catheters may be used in an outpatient
setting similarly to the procedure we described in the
present study. However, no sclerosing agent is adminis-
tered and patients remain with the catheter for long time
and are supposed to periodically drain their own fluid using
dedicated vacuum bottles. Interestingly, spontaneous pleur-
odesis has been observed after a mean time of 90 days in
about 70% of patients fit for pleurodesis who underwent
long-term pleural catheters insertion.18 Failure in studies
addressing long-term indwelling catheters is frequently
defined as the need of additional pleural procedures. In our
study, additional procedures were necessary in 11.5% of the
patients, whether due to MPE recurrence or because of
infectious complications, on the other hand in a series of 223
patients who underwent long-term catheter implantation,
the need for additional pleural procedures was 9.9%.16
However, these patients remained with the drain in place
for an average of 56 days (compared with 9.9 days in the
present study). Long-term drainage is a frequent finding in
long-term indwelling catheter series and a drawback of such
a technique. It was observed that 41.4–45.8% of these
patients die with the drain in place, and in those where it
is possible to remove the catheter, they remain in the pleural
cavity for an average of 29.4–59 days.16,17 Not only long
term-drainage but also device availability, costs, and
cultural issues - particularly the ability to deal with the
device and the willingness to remain with a drain for long
periods - are matters of concern.
We observed trapped lung in 21% of our patients and
other authors had also failed in identify such features before
drainage and found 15 and 20% of patients with trapped
lung.4,15 In spite of the fact that such patients had been
excluded from the pleurodesis trial, we followed them, and
we have found some significant results. From a clinical
perspective, the most important finding was the high
empyema rate (28.5%) in those who had trapped lung and
long-term drainage. In the trapped lung subset of patients,
the empyema rate was higher than in those series which
long-term indwelling catheters were used.16,17 One possible
explanation for this observation might be the fact that pig-
tail catheters are not tunneled; therefore,superficial infec-
tions would reach the pleural cavity more easily and cause
empyema. Therefore, our policy now is to remove chest
drains as soon as possible in the event of trapped lung.
The following aspects of this study weaken our conclu-
sions, as a prospective cohort, no comparisons were made
with other pertinent techniques, such as pleurodesis by
videothoracoscopy or long-term pleural catheters; and, none
of the investigators was blinded therefore the number of
recurrences and complications might be underestimated.
Moreover, talc was the only agent tested and different
sclerosing agents as belomicyn, iodopovidone or silver
nitrate could provide different results.19,20 Unfortunately,
the small number of patients did not enable us to identify
risk factors for complications, recurrence, and mortality
within 30 days, which would be particularly interesting for
specifying those patients who would most benefit from this
treatment.
CONCLUSIONS
We can conclude that the strategy used in this study
enabled adequate control of pleural effusion symptomatol-
ogy and was associated with the level of recurrence and the
need for additional procedures similar to those of other
methods described in the literature. In addition, this
technique offers
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